Correction to: Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-019-0063-8, published online 23 August 2019
Since the publication of this Review Article, we noticed several mistakes in Table 2 and the Perspective section that need to be corrected immediately.
In Table 2, the status of AAB-003 Phase I trial is completed. In addition, the status of GV-971 Phase III trial is completed in China. The correct portion of Table 2 is displayed as below.
In the perspective section, the sigma-1 receptor activator Anavex 2-73 has entered a phase III clinical trial but it was not granted fast-track status by the FDA. Therefore, the texts should be corrected to “In addition, fluoxetine can bind to the endoplasmic reticulum protein sigma-1 receptor.418 Sigma-1 receptor ligands can enhance acetylcholine secretion.419,420 The sigma-1 receptor is located in the mitochondrion-associated ER membrane so that the activation of the sigma-1 receptor can prolong Ca2+ signaling in mitochondria.421 Consequently, the local and specific elevation of [Ca2+] in the mitochondrial matrix can enhance ATP synthesis,422,423 which ameliorates hypometabolism. Interestingly, Anavex 2-73, a sigma-1 receptor activator is now in phase III clinical trial.”
The key messages of the article are not affected by these corrections. We apologize for these inadvertent mistakes.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Liu, PP., Xie, Y., Meng, XY. et al. Author Correction: History and progress of hypotheses and clinical trials for Alzheimer’s disease. Sig Transduct Target Ther 4, 37 (2019). https://doi.org/10.1038/s41392-019-0071-8
Published:
DOI: https://doi.org/10.1038/s41392-019-0071-8
This article is cited by
-
The GABAergic system in Alzheimer’s disease: a systematic review with meta-analysis
Molecular Psychiatry (2023)
-
Challenges and Opportunities of Metal Chelation Therapy in Trace Metals Overload-Induced Alzheimer’s Disease
Neurotoxicity Research (2023)